1. Home
  2. STRT vs NGEN Comparison

STRT vs NGEN Comparison

Compare STRT & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo STRATTEC SECURITY CORPORATION

STRT

STRATTEC SECURITY CORPORATION

HOLD

Current Price

$90.72

Market Cap

331.1M

ML Signal

HOLD

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$4.14

Market Cap

317.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
STRT
NGEN
Founded
1908
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
331.1M
317.6M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
STRT
NGEN
Price
$90.72
$4.14
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
34.5K
128.3K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
12.53
N/A
EPS
3.26
N/A
Revenue
$439,195,000.00
N/A
Revenue This Year
$4.22
N/A
Revenue Next Year
$2.04
N/A
P/E Ratio
$27.89
N/A
Revenue Growth
5.24
N/A
52 Week Low
$31.71
$3.73
52 Week High
$92.50
$5.93

Technical Indicators

Market Signals
Indicator
STRT
NGEN
Relative Strength Index (RSI) 59.53 37.03
Support Level $62.09 $3.73
Resistance Level $92.45 $4.50
Average True Range (ATR) 4.48 0.23
MACD -0.08 0.06
Stochastic Oscillator 85.91 45.45

Price Performance

Historical Comparison
STRT
NGEN

About STRT STRATTEC SECURITY CORPORATION

Strattec Security Corp designs develops, manufactures, and markets mechanical locks, electronically enhanced locks, and keys. It also produces ignition lock housings; and access control products, including latches, power sliding door systems, and door handles. Strattec ships products to customer locations in the United States, Canada, Mexico, Europe, South America, Korea, and China, and provides full-service aftermarket support. Strattec also supplies products for the heavy truck and recreational vehicle markets, as well as precision, die castings.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: